Search

Your search keyword '"Pusceddu S."' showing total 274 results
Start Over Author "Pusceddu S."
274 results on '"Pusceddu S."'

1. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Published
2024
Full Text
View/download PDF

2. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Author

Massironi, S., Campana, D., Pusceddu, S., Albertelli, M., Faggiano, A., Panzuto, F., Smiroldo, V., Andreasi, V., Rossi, R.E., Maggio, I., Torchio, M., Dotto, A., Modica, R., Rinzivillo, M., Carnaghi, C., Partelli, S., Fanetti, I., Lamberti, G., Corti, F., Ferone, D., Colao, A., Annibale, B., Invernizzi, P., and Falconi, M.

Published
2021
Full Text
View/download PDF

4. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., Maccauro, M., Campana, D., Faggiano, A., Massironi, S., Pusceddu, S., Spada, F., Ferone, D., Modica, R., Grana, C. M., Ferolla, P., Rinzivillo, M., Badalamenti, G., Zatelli, M. C., Gelsomino, F., De Carlo, E., Bartolomei, M., Brizzi, M. P., Cingarlini, S., Versari, A., Fanciulli, G., Arvat, E., Merola, E., Cives, M., Tafuto, S., Baldari, S., and Falconi, M.

Published
2021
Full Text
View/download PDF

5. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, and Spada, Francesca

Abstract

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.

Published
2023

6. 31P Bone metastases and skeletal related events in pheochromocytoma and paraganglioma patients: International, retrospective study

Author

Laganà, M., primary, Cosentini, D., additional, Grisanti, S., additional, Remde, H., additional, Almeida, M., additional, Pusceddu, S., additional, Deutschbein, T., additional, Fagundes, G., additional, Pereira, A., additional, Grana, C.M., additional, Fazio, N., additional, Corssmit, E., additional, Bongiovanni, A., additional, Canu, L., additional, Kim, E., additional, Habra, M., additional, Jimenez, C., additional, and Berruti, A., additional

Published
2023
Full Text
View/download PDF

8. Novel morphological tools in predicting pancreatic neuroendocrine tumors (Pan-Net) clinical outcome

Author

Lagano V, Sabella G, Cattaneo L, Grillo F, Mangogna A, Prinzi N, Pusceddu S, Simbolo M, Scarpa Aldo, Mazzaferro V, Centonze G, Milione M, Lagano, V, Sabella, G, Cattaneo, L, Grillo, F, Mangogna, A, Prinzi, N, Pusceddu, S, Simbolo, M, Scarpa, Aldo, Mazzaferro, V, Centonze, G, and Milione, M

Subjects
Pancreas, Parenchymal infiltration, Tumor deposits, Pancrea
Abstract

Introduction: Pancreatic Neuroendocrine Tumor (Pan-NET) clinical outcome shows a high variability among patients within the same World Health Organization (WHO) category. To date, there is a lack of markers to predict recurrence after resection, which makes it difficult to identify patients with higher risk of progression. Aim(s): To evaluate morphologic and clinicopathological features of surgically resected Pan-NET. Materials and methods: Surgical specimens of 150 Pan-NET patients were evaluated for the following diagnostic and prognostic tools: Tumor stage, Ki-67, parenchymal infiltration, neural and vascular invasion, tumor necrosis or sclerosis and tumor deposits. These data were correlated with Overall Survival (OS) and stage I-II-III Disease-Free Survival (DFS). Results: Overall, 76 (50.7%) patients showed localized (stage I-II), 22 (14.7%) locally advanced (stage III), and 52 (34.7%) metastatic disease (stage IV). Tumor size >2 cm (p

Published
2022

9. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Author

Massironi, S, Campana, D, Pusceddu, S, Albertelli, M, Faggiano, A, Panzuto, F, Smiroldo, V, Andreasi, V, Rossi, R, Maggio, I, Torchio, M, Dotto, A, Modica, R, Rinzivillo, M, Carnaghi, C, Partelli, S, Fanetti, I, Lamberti, G, Corti, F, Ferone, D, Colao, A, Annibale, B, Invernizzi, P, Falconi, M, Massironi S., Campana D., Pusceddu S., Albertelli M., Faggiano A., Panzuto F., Smiroldo V., Andreasi V., Rossi R. E., Maggio I., Torchio M., Dotto A., Modica R., Rinzivillo M., Carnaghi C., Partelli S., Fanetti I., Lamberti G., Corti F., Ferone D., Colao A., Annibale B., Invernizzi P., Falconi M., Massironi, S, Campana, D, Pusceddu, S, Albertelli, M, Faggiano, A, Panzuto, F, Smiroldo, V, Andreasi, V, Rossi, R, Maggio, I, Torchio, M, Dotto, A, Modica, R, Rinzivillo, M, Carnaghi, C, Partelli, S, Fanetti, I, Lamberti, G, Corti, F, Ferone, D, Colao, A, Annibale, B, Invernizzi, P, Falconi, M, Massironi S., Campana D., Pusceddu S., Albertelli M., Faggiano A., Panzuto F., Smiroldo V., Andreasi V., Rossi R. E., Maggio I., Torchio M., Dotto A., Modica R., Rinzivillo M., Carnaghi C., Partelli S., Fanetti I., Lamberti G., Corti F., Ferone D., Colao A., Annibale B., Invernizzi P., and Falconi M.

Abstract

Background: Patients with sporadic neuroendocrine neoplasms may exhibit a higher risk of a second primary tumor than the general population. Aim: This study aimed to analyze the occurrence of second primary malignancies. Methods: A retrospective cohort of 2757 patients with sporadic lung and gastro-entero-pancreatic neuroendocrine neoplasms, managed at eight Italian tertiary referral Centers, was included. Results: Between 2000 and 2019, a second primary malignancy was observed in 271 (9.8%) neuroendocrine neoplasms patients with 32 developing a third tumor. There were 135 (49.8%) females and the median age was 64 years. The most frequent locations of the second tumors were breast (18.8%), prostate (12.5%), colon (9.6%), blood tumors (8.5%), and lung (7.7%). The second primary tumor was synchronous in 19.2% of cases, metachronous in 43.2%, and previous in 37.6%. As concerned the neuroendocrine neoplasms, the 5- and 10-year survival rates were 87.8% and 74.4%, respectively. PFS for patients with a second primary malignancy was shorter than for patients without a second primary malignancy. Death was mainly related to neuroendocrine neoplasms. Conclusion: In NEN patients the prevalence of second primary malignancies was not negligible, suggesting a possible neoplastic susceptibility. Overall survival was not affected by the occurrence of a second primary malignancy.

Published
2021

11. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

Author

Ricci, C., Pusceddu, S., Prinzi, N., Tafuto, S., Ibrahim, T., Filice, A., Brizzi, M. P., Panzuto, F., Baldari, S., Grana, C. M., Campana, D., Davi, M. V., Giuffrida, D., Zatelli, M. C., Partelli, S., Razzore, P., Marconcini, R., Massironi, S., Gelsomino, F., Faggiano, A., Giannetta, E., Bajetta, E., Grimaldi, F., Cives, M., Cirillo, F., Perfetti, V., Corti, F., Giacomelli, L., Porcu, L., Di Maio, M., Seregni, E., Maccauro, M., Lastoria, S., Bongiovanni, A., Versari, A., Persano, I., Rinzivillo, M., Pignata, S. A., Rocca, P. A., Lamberti, G., Cingarlini, S., Puliafito, I., Ambrosio, M. R., Zanata, I., Bracigliano, A., Severi, S., Spada, F., Andreasi, V., Modica, R., Scalorbi, F., Milione, M., Sabella, G., Coppa, J., Casadei, R., Di Bartolomeo, M., Falconi, M., De Braud, F., Pusceddu, Sara, Prinzi, Natalie, Tafuto, Salvatore, Ibrahim, Toni, Filice, Angelina, Brizzi, Maria Pia, Panzuto, Francesco, Baldari, Sergio, Grana, Chiara M., Campana, Davide, Davì, Maria Vittoria, Giuffrida, Dario, Zatelli, Maria Chiara, Partelli, Stefano, Razzore, Paola, Marconcini, Riccardo, Massironi, Sara, Gelsomino, Fabio, Faggiano, Antongiulio, Giannetta, Elisa, Bajetta, Emilio, Grimaldi, Franco, Cives, Mauro, Cirillo, Fernando, Perfetti, Vittorio, Corti, Francesca, Ricci, Claudio, Giacomelli, Luca, Porcu, Luca, Di Maio, Massimo, Seregni, Ettore, Maccauro, Marco, Lastoria, Secondo, Bongiovanni, Alberto, Versari, Annibale, Persano, Irene, Rinzivillo, Maria, Pignata, Salvatore Antonio, Rocca, Paola Anna, Lamberti, Giuseppe, Cingarlini, Sara, Puliafito, Ivana, Ambrosio, Maria Rosaria, Zanata, Isabella, Bracigliano, Alessandra, Severi, Stefano, Spada, Francesca, Andreasi, Valentina, Modica, Roberta, Scalorbi, Federica, Milione, Massimo, Sabella, Giovanna, Coppa, Jorgelina, Casadei, Riccardo, Di Bartolomeo, Maria, Falconi, Massimo, de Braud, Filippo, Grana, Chiara M, and Davi, Maria Vittoria

Subjects
Male, Radiotherapy, Receptors, Peptide, General Medicine, sequence, Middle Aged, peptide receptors radionuclide therapy, everolimus, chemotherapy, Progression-Free Survival, NO, Peptide Receptor Radionuclide Therapy, Pancreatic Neoplasms, Neuroendocrine Tumors, receptor radionuclide therapy, enteropancreatic neuroendocrine tumors, progression free survival, Receptors, Peptide, Humans, Female, LS4_3, neuroendocrine tumors, sequence, everolimus, Retrospective Studies
Abstract

Importance: Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. Objective: To evaluate the association of upfront PRRT vs upfront chemotherapy or targeted therapy with progression-free survival (PFS) among patients with advanced enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues (SSAs). Design, setting, and participants: This retrospective, multicenter cohort study analyzed the clinical records from 25 Italian oncology centers for patients aged 18 years or older who had unresectable, locally advanced or metastatic, well-differentiated, grades 1 to 3 enteropancreatic neuroendocrine tumors and received either PRRT or chemotherapy or targeted therapy after experiencing disease progression after treatment with SSAs between January 24, 2000, and July 1, 2020. Propensity score matching was done to minimize the selection bias. Exposures: Upfront PRRT or upfront chemotherapy or targeted therapy. Main outcomes and measures: The main outcome was the difference in PFS among patients who received upfront PRRT vs among those who received upfront chemotherapy or targeted therapy. A secondary outcome was the difference in overall survival between these groups. Hazard ratios (HRs) were fitted in a multivariable Cox proportional hazards regression model to adjust for relevant factors associated with PFS and were corrected for interaction with these factors. Results: Of 508 evaluated patients (mean ([SD] age, 55.7 [0.5] years; 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy. The matched group included 222 patients (124 [55.9%] male; mean [SD] age, 56.1 [0.8] years), with 111 in each treatment group. Median PFS was longer in the PRRT group than in the chemotherapy or targeted therapy group in the unmatched (2.5 years [95% CI, 2.3-3.0 years] vs 0.7 years [95% CI, 0.5-1.0 years]; HR, 0.35 [95% CI, 0.28-0.44; P

Published
2022

12. 1105P Predictive factors of adverse events onset in GEPNET patients treated with PRRT

Author

Scalorbi, F., primary, Argiroffi, G., additional, Lorenzoni, A., additional, Baccini, M., additional, Gherardini, L., additional, Fuoco, V., additional, Prinzi, N., additional, Pusceddu, S., additional, Calareso, G., additional, Garanzini, E., additional, Centonze, G., additional, Milione, M., additional, Chiesa, C., additional, Seregni, E., additional, and Maccauro, M., additional

Published
2021
Full Text
View/download PDF

15. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Abstract

Background: The incidence of neuroendocrine neoplasm (NEN) and related carcinoid syndrome (CaS) has increased markedly in recent decades, and women appear to be more at risk than men. As per other tumors, gender may be relevant in influencing the clinical and prognostic characteristics of NEN-associated CS. However, specific data on carcinoid syndrome (CaS) are still lacking. Purpose: To evaluate gender differences in clinical presentation and outcome of CaS. Methods: Retrospective analysis of 144 CaS patients from 20 Italian high-volume centers was conducted. Clinical presentation, tumor characteristics, therapies, and outcomes (progression-free survival, PFS, overall survival, OS) were correlated to gender. Results: Ninety (62.5%) CaS patients were male. There was no gender difference in the site of primary tumor, tumor grade and clinical stage, as well as in treatments. Men were more frequently smokers (37.2%) and alcohol drinkers (17.8%) than women (9.5%, p= 0.002, and 3.7%, p= 0.004, respectively). Concerning clinical presentation, women showed higher median number of symptoms (p= 0.0007), more frequent abdominal pain, tachycardia, and psychiatric disorders than men (53.3% vs 70.4%, p= 0.044; 6.7% vs 31.5%, p= 0.001; 50.9% vs. 26.7%, p= 0.003, respectively). Lymph node metastases at diagnosis were more frequent in men than in women (80% vs 64.8%; p= 0.04), but no differences in terms of PFS (p= 0.51) and OS (p= 0.64) were found between gender. Conclusions: In this Italian cohort, CaS was slightly more frequent in males than females. Gender-related differences emerged in the clinical presentation of CaS, as well as gender-specific risk factors for CaS development. A gender-driven clinical management of these patients should be advisable.

Published
2023
Full Text
View/download PDF

16. T03.01.15 SECOND PRIMARY NEOPLASMS IN PATIENTS WITH GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NEN): DATA FROM A RETROSPECTIVE IT.A.NET STUDY

Author

Massironi, S., primary, Campana, D., additional, Pusceddu, S., additional, Albertelli, M., additional, Faggiano, A., additional, Panzuto, F., additional, Smiroldo, V., additional, Andreasi, V., additional, Rossi, R.E., additional, Maggio, I., additional, Torchio, M., additional, Ambrosetti, E., additional, Modica, R., additional, Rinzivillo, M., additional, Carnaghi, C., additional, Partelli, S., additional, Fanetti, I., additional, Lamberti, G., additional, Corti, F., additional, Dotto, A., additional, Colao, A., additional, Annibale, B., additional, Falconi, M., additional, and Invernizzi, P., additional

Published
2020
Full Text
View/download PDF

17. 1182P Baseline neutrophil-lymphocyte ratio and its variations after adjuvant radiotherapy predict clinical survival outcomes in locally advanced Merkel cell carcinoma (MCC)

Author

Torchio, M., primary, Corti, F., additional, Manca, P., additional, Prinzi, N., additional, Platania, M., additional, Maurichi, A., additional, Mattavelli, I., additional, Patuzzo, R., additional, Bedini, N., additional, Milione, M., additional, Cattaneo, L., additional, Beninato, T., additional, Prisciandaro, M., additional, Raimondi, A., additional, Pagani, F., additional, Colombo, E., additional, Coppa, J., additional, Di Bartolomeo, M., additional, de Braud, F.G., additional, and Pusceddu, S., additional

Published
2020
Full Text
View/download PDF

18. 1183P Sequential PRRT and SIRT: Evaluation of safety, toxicity and best sequence treatment in liver dominant GEPNETs

Author

Scalorbi, F., primary, Lorenzoni, A., additional, Mazzaglia, S., additional, Garanzini, E., additional, Chiesa, C., additional, Aliberti, G., additional, Argiroffi, G., additional, Pusceddu, S., additional, Prinzi, N., additional, Spreafico, C., additional, Centonze, G., additional, Coppa, J., additional, Marchianò, A., additional, Milione, M., additional, Mazzaferro, V., additional, Seregni, E., additional, and Maccauro, M., additional

Published
2020
Full Text
View/download PDF

21. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., primary, Maccauro, M., additional, Campana, D., additional, Faggiano, A., additional, Massironi, S., additional, Pusceddu, S., additional, Spada, F., additional, Ferone, D., additional, Modica, R., additional, Grana, C. M., additional, Ferolla, P., additional, Rinzivillo, M., additional, Badalamenti, G., additional, Zatelli, M. C., additional, Gelsomino, F., additional, De Carlo, E., additional, Bartolomei, M., additional, Brizzi, M. P., additional, Cingarlini, S., additional, Versari, A., additional, Fanciulli, G., additional, Arvat, E., additional, Merola, E., additional, Cives, M., additional, Tafuto, S., additional, Baldari, S., additional, and Falconi, M., additional

Published
2020
Full Text
View/download PDF

22. PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB

Author

Bharmal, M., primary, Nolte, S., additional, Lebbe, C., additional, Mortier, L., additional, Brohl, A.S., additional, Fazio, N., additional, Grob, J.J., additional, Pusceddu, S., additional, Hanna, G.J., additional, Hassel, J.C., additional, Kiecker, F., additional, Ellers-Lenz, B., additional, Bajars, M., additional, Güzel, G., additional, Nghiem, P., additional, Hunger, M., additional, Schlichting, M., additional, Henry-Szatkowski, M., additional, and D'Angelo, S.P., additional

Published
2020
Full Text
View/download PDF

23. Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study

Author

Veltroni, A, primary, Cosaro, E, additional, Spada, F, additional, Fazio, N, additional, Faggiano, A, additional, Colao, A, additional, Pusceddu, S, additional, Zatelli, M C, additional, Campana, D, additional, Piovesan, A, additional, Pia, A, additional, Grossrubatscher, E M, additional, Filice, A, additional, Bianchi, A, additional, Razzore, P, additional, Toaiari, M, additional, Cingarlini, S, additional, Landoni, L, additional, Micciolo, R, additional, and Davì, M V, additional

Published
2020
Full Text
View/download PDF

24. Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

Author

Cani, M., primary, Incorvaia, L., additional, Fanale, D., additional, De Luca, I., additional, Gelsomino, F., additional, Ibrahim, T., additional, Pusceddu, S., additional, Riccardi, F., additional, Tafuto, S., additional, Lamberti, G., additional, Faggiano, A., additional, La salvia, A., additional, Albertelli, M., additional, Massironi, S., additional, Rinzivillo, M., additional, butturini, G., additional, Bazan, V., additional, Campana, D., additional, Russo, A., additional, and Badalamenti, G., additional

Published
2019
Full Text
View/download PDF

25. Is MGMT methylation a new therapeutic target for biliary tract cancer?

Author

Niger, M., primary, Morano, F., additional, Manglaviti, S., additional, Nichetti, F., additional, Tamborini, E., additional, Perrone, F., additional, Marcuzzo, M., additional, Peverelli, G., additional, Brambilla, M., additional, Pagani, F., additional, Torchio, M., additional, Ottini, A., additional, Antista, M., additional, Pietrantonio, F., additional, Pusceddu, S., additional, Pruneri, G., additional, Di Bartolomeo, M., additional, and De Braud, F.G.M., additional

Published
2019
Full Text
View/download PDF

26. MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience

Author

Niger, M., primary, Morano, F., additional, Manglaviti, S., additional, Nichetti, F., additional, Perrone, F., additional, Tamborini, E., additional, Marcuzzo, M., additional, Raimondi, A., additional, Peverelli, G., additional, Brambilla, M., additional, Pagani, F., additional, Torchio, M., additional, Prisciandaro, M., additional, Antista, M., additional, Pietrantonio, F., additional, Pusceddu, S., additional, Pruneri, G., additional, De Braud, F.G.M., additional, and Di Bartolomeo, M., additional

Published
2019
Full Text
View/download PDF

27. P.03.1 PROGNOSTIC IMPACT OF TUMOR BURDEN IN STAGE IV NEUROENDOCRINE NEOPLASIA: COMPARISON BETWEEN PANCREATIC AND GASTROINTESTINAL LOCALIZATIONS

Author

Panzuto, F., primary, Campana, D., additional, Pusceddu, S., additional, Faggiano, A., additional, Rinzivillo, M., additional, Brighi, N., additional, Prinzi, N., additional, Riccardi, F., additional, Iannicelli, E., additional, Maggio, I., additional, Fermia, D., additional, Tafuto, S., additional, Manuzzi, L., additional, Colao, A., additional, De Braud, F., additional, and Annibale, B., additional

Published
2019
Full Text
View/download PDF

28. The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., primary, Seregni, E., additional, Raimondi, A., additional, Maccauro, M., additional, Corti, F., additional, Lo Russo, G., additional, Nichetti, F., additional, Torchio, M., additional, Coppa, J., additional, Peverelli, G., additional, Pagani, F., additional, Di Bartolomeo, M., additional, Mazzaferro, V., additional, de Braud, F., additional, and Pusceddu, S., additional

Published
2018
Full Text
View/download PDF

29. Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)

Author

Pusceddu, S., primary, Vernieri, C., additional, Di Maio, M., additional, Prinzi, N., additional, Torchio, M., additional, Buzzoni, R., additional, Truong-Thanh, X.-M., additional, Mazzaferro, V., additional, and de Braud, F.G.M., additional

Published
2018
Full Text
View/download PDF

30. CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)

Author

Bongiovanni, A., primary, Pusceddu, S., additional, Leo, S., additional, Di meglio, G., additional, Gelsomino, F., additional, Pucci, F., additional, Berardi, R., additional, Ricci, S., additional, Lolli, I., additional, Bergamo, F., additional, Campana, D., additional, Santini, D., additional, Tamberi, S., additional, Pastorelli, D., additional, Cives, M., additional, Silvestris, N., additional, Russo, A., additional, Buonadonna, A., additional, Foca, F., additional, and Ibrahim, T., additional

Published
2018
Full Text
View/download PDF

31. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Author

Yao, J.C., primary, Strosberg, J., additional, Fazio, N., additional, Pavel, M.E., additional, Ruszniewski, P., additional, Bergsland, E., additional, Li, D., additional, Tafuto, S., additional, Raj, N., additional, Campana, D., additional, Hijioka, S., additional, Raderer, M., additional, Guimbaud, R., additional, Gajate, P., additional, Pusceddu, S., additional, Reising, A., additional, Degtyarev, E., additional, Mookerjee, B., additional, Aimone, P., additional, and Singh, S., additional

Published
2018
Full Text
View/download PDF

33. Real-world study of everolimus in advanced progressive neuroendocrine tumors

Author

Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Panzuto, F, Rinzivillo, M, Fazio, N, de Braud, F, Luppi, G, Zatelli, Mc, Lugli, F, Tomassetti, P, Riccardi, F, Nuzzo, C, Brizzi, Mp, Faggiano, A, Zaniboni, A, Nobili, E, Pastorelli, D, Cascinu, S, Merlano, M, Chiara, S, Antonuzzo, L, Funaioli, C, Spada, F, Pusceddu, S, Fontana, A, Ambrosio, Mr, Cassano, A, Campana, D, Cartenì, G, Appetecchia, M, Berruti, A, Colao, A, and Falconi, M

Published
2015

35. Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management

Author

Fazio, N., primary, Maisonneuve, P., additional, Frezza, A.M., additional, Ibrahim, T., additional, La Salvia, A., additional, Tafuto, S., additional, Pusceddu, S., additional, Marconcini, R., additional, Silvestris, F., additional, Campana, D., additional, Santini, D., additional, Faggiano, A., additional, Massironi, S., additional, De Marinis, L., additional, Rubini, G., additional, Merola, E., additional, Antonuzzo, L., additional, Amoroso, V., additional, Puliafito, I., additional, and Spada, F., additional

Published
2017
Full Text
View/download PDF

40. Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study

Author

Pusceddu, S., primary, Marconcini, R., additional, Spada, F., additional, Massironi, S., additional, Bongiovanni, A., additional, Brizzi, M.P., additional, Brighi, N., additional, Colao, A., additional, Giuffrida, D., additional, De Fave, Glle, additional, Cingarlini, S., additional, Aroldi, F., additional, Antonuzzo, L., additional, Berardi, R., additional, Catena, L., additional, de divitis, C., additional, Ermacora, P., additional, Di Maio, M., additional, Buzzoni, R., additional, and de Braud, F., additional

Published
2016
Full Text
View/download PDF

41. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)

Author

Berardi, R., primary, Torniai, M., additional, Pusceddu, S., additional, Spada, F., additional, Ibrahim, T., additional, Zichi, C., additional, Antonuzzo, L., additional, Ferolla, P., additional, Rinzivillo, M., additional, Silvestris, N., additional, Partelli, S., additional, Ferretti, B., additional, Bongiovanni, A., additional, Giustini, L., additional, Di Costanzo, F., additional, Delle Fave, G., additional, Fazio, N., additional, De Braud, F.G.M., additional, Falconi, M., additional, and Cascinu, S., additional

Published
2016
Full Text
View/download PDF

42. Safety of lanreotide 120 mg ATG in combination with metformin in patients with advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: The MetNET-2 trial

Author

De Braud, F.G.M., primary, Buzzoni, R., additional, Concas, L., additional, Femia, D., additional, Prinzi, N., additional, Milione, M., additional, Tamborini, E., additional, Perrone, F., additional, Russo, G.L.o., additional, Vernieri, C., additional, Pulice, I., additional, Piras, F., additional, Dinoi, G., additional, and Pusceddu, S., additional

Published
2016
Full Text
View/download PDF

44. Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial

Author

Buzzoni, R., primary, Filippo, D.B., additional, Femia, D., additional, Prinzi, N., additional, Concas, L., additional, Milione, M., additional, Tamborini, E., additional, Perrone, F., additional, Lo Russo, G., additional, Vernieri, C., additional, Pulice, I., additional, Piras, F., additional, Dinoi, G., additional, and Pusceddu, S., additional

Published
2016
Full Text
View/download PDF

45. Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result

Author

Lamberti, G., primary, Rossi, G., additional, Grillo, F., additional, Spada, F., additional, Pusceddu, S., additional, Rinzivillo, M., additional, Massironi, S., additional, Tafuto, S., additional, Faggiano, A., additional, Antonuzzo, L., additional, Luppi, G., additional, Albertelli, M., additional, Fazio, N., additional, Vernieri, C., additional, Delle Fave, G., additional, Brighi, N., additional, Ferone, D., additional, and Campana, D., additional

Published
2016
Full Text
View/download PDF

47. 1324P - The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., Seregni, E., Raimondi, A., Maccauro, M., Corti, F., Lo Russo, G., Nichetti, F., Torchio, M., Coppa, J., Peverelli, G., Pagani, F., Di Bartolomeo, M., Mazzaferro, V., de Braud, F., and Pusceddu, S.

Published
2018
Full Text
View/download PDF

49. 1308O - Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Author

Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E., Li, D., Tafuto, S., Raj, N., Campana, D., Hijioka, S., Raderer, M., Guimbaud, R., Gajate, P., Pusceddu, S., Reising, A., Degtyarev, E., Mookerjee, B., Aimone, P., and Singh, S.

Published
2018
Full Text
View/download PDF

50. Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update

Author

Bajetta, E., primary, Catena, L., additional, Pusceddu, S., additional, Fazio, N., additional, Blanco, G., additional, Ricci, S., additional, Aieta, M., additional, Pucci, F., additional, Sarno, I., additional, Spada, F., additional, Di Menna, G., additional, and Dottorini, L., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results